Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DMMQFG2)

Drug Name	Imeglimin DMMQFG2
Synonyms	775351-65-0; UNII-UU226QGU97; UU226QGU97; Imeglimin [INN]; Emd 387008 (R-imeglimin) HCl; SCHEMBL2158106; SCHEMBL14868241; C6H13N5; DTXSID50228237; BCP11085; ZINC34380900; 3733AH; AKOS027338676; DB12509; CS-1751; HY-14771
Drug Type	Small molecular drug
Structure
Structure	3D MOL			2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

2 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Type-2 diabetes	DIS3X247	5A11	Phase 2	[1]
Diabetic complication	DIS4S2FC	5A2Y	Phase 2	[2]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01951235) A Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes. U.S. National Institutes of Health.
2	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032542)